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The folate and methionine cycles are crucial for biosynthesis of lipids, nucleotides and pro-
teins, and production of the methyl donor S-adenosylmethionine (SAM). 5,10-methylene-
tetrahydrofolate reductase (MTHFR) represents a key regulatory connection between these
cycles, generating 5-methyltetrahydrofolate for initiation of the methionine cycle, and
undergoing allosteric inhibition by its end product SAM. Our 2.5 Å resolution crystal structure
of human MTHFR reveals a unique architecture, appending the well-conserved catalytic TIM-
barrel to a eukaryote-only SAM-binding domain. The latter domain of novel fold provides the
predominant interface for MTHFR homo-dimerization, positioning the N-terminal serine-rich
phosphorylation region near the C-terminal SAM-binding domain. This explains how MTHFR
phosphorylation, identiﬁed on 11 N-terminal residues (16 in total), increases sensitivity to
SAM binding and inhibition. Finally, we demonstrate that the 25-amino-acid inter-domain
linker enables conformational plasticity and propose it to be a key mediator of SAM reg-
ulation. Together, these results provide insight into the molecular regulation of MTHFR.
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In humans, the folate and methionine cycles both generateproducts essential to cellular survival. Folate, the major cellularcarrier of single carbon units, is required for the synthesis of
purines and thymidine monophosphate. Within the methionine
cycle, the methylation of homocysteine to methionine by
methionine synthase (EC 2.1.1.13) produces an essential amino
acid which may be used for protein synthesis or, crucially, be
further converted to S-adenosylmethionine (SAM), a vitally
important donor for the methylation of DNA, RNA and proteins
as well as the creation of numerous methylated compounds.
These two cycles intersect at the enzyme 5,10-methylenete-
trahydrofolate reductase (MTHFR; E.C. 1.5.1.20). MTHFR cata-
lyzes the physiologically irreversible reduction of 5,10-methylene-
tetrahydrofolate (CH2-THF) to 5-methyl-tetrahydrofolate (CH3-
THF), a reaction requiring FAD as a cofactor and NADPH as an
electron donor. Since the product CH3-THF is exclusively used by
methionine synthase, and only the demethylated form (THF)
may be recycled back to the folate cycle, MTHFR commits THF-
bound one-carbon units to the methionine cycle.
In accordance with this essential role, major and minor deﬁ-
ciencies of human MTHFR are the direct or indirect causes of
human disease. Severe MTHFR deﬁciency (MIM #607093) is
inherited in an autosomal recessive manner and is the most
common inborn error of folate deﬁciency1 with ~200 patients
known2. To date, over 100 different clinically relevant mutations
in MTHFR have been described, the majority of which are of the
missense type (n= 70, >60%) and private2. Milder enzyme deﬁ-
ciencies, due to single nucleotide polymorphisms of the MTHFR
gene, have been associated with various common disorders.
The most studied of these is p.Ala222Val (c.665C>T in
NM_001330358, commonly annotated as c.677C>T), identiﬁed as
a risk factor for an overwhelming number of multifactorial dis-
orders, including vascular diseases, neurological diseases, various
cancers, diabetes and pregnancy loss (see e.g. review by Liew and
Gupta3).
Human MTHFR is a 656 amino acid multi-domain protein
(Fig. 1). The catalytic domain is conserved across evolution, and
crystal structures of MTHFR from Escherichia (E.) coli4–7 and
Thermus thermophilus8, in which the catalytic domain constitutes
the entire sequence (Fig. 1), have been solved. These structures
reveal the catalytic domain to form a β8α8 (TIM) barrel and have
uncovered residues critical for binding the cofactor FAD4, the
electron donor NADPH (NADH in bacteria7) and the product
CH3-THF5–7. The bacterial structures, together with activity assay
of trypsin cleaved porcine MTHFR9, indicate that the catalytic
domain is sufﬁcient for the entire catalytic cycle. Eukaryotic
MTHFR orthologs additionally possess a C-terminal regulatory
domain that is connected to the catalytic domain by a linker
sequence (Fig. 1). This C-terminal domain is able to bind SAM,
resulting in allosteric inhibition of enzymatic activity10, an
effect which is very slow11 and can be reversed by binding
to S-adenosylhomocysteine (SAH)12,13, the demethylated form of
SAM.
Human MTHFR further contains a 35 amino acid serine-rich
region at the very N-terminus which is not found in MTHFR
orthologs of bacteria, yeast or even lower animals (Fig. 1). This
region has been identiﬁed to be multiply phosphorylated fol-
lowing heterologous expression in insect cells14 and yeast15, or
following immunoprecipitation from human cancer cell lines16.
Phosphorylation has been associated with moderately decreased
catalytic activity14–16 and increased total inhibition mediated by
SAM14. Although phosphorylation mapping of this region has
been thus far unsuccessful, scanning mutagenesis has revealed
substitution of alanine for threonine at position 34 (p.Thr34Ala)
to almost completely block phosphorylation14,15, suggesting
Thr34 is the priming position. The cellular relevance of this
modiﬁcation remains unclear, although one group has suggested
that phosphorylation at Thr34 can be accomplished by CDK1/
cyclin B1 (ref. 16) and at Thr549 by polo-like kinase 1 (ref. 17)
whereby they posit a role in histone methylation and replication.
The repertoire of bacterial MTHFR structures to date does not
provide any mechanistic insight into the enzymatic regulation by
phosphorylation and SAM binding, because both features are
absent in prokaryotes. To this end, we have combined structural,
biophysical and biochemical data of human MTHFR to provide a
molecular view of MTHFR function and regulation in higher
eukaryotes. We have identiﬁed speciﬁc phosphorylation sites and
demonstrate a distinct relationship between phosphorylation and
SAM inhibition. Further, using our 2.5 Å resolution crystal
structure of the almost full-length human protein, we reveal that
the regulatory domain utilizes a unique topology to bind SAH/
SAM and transmit a catalytic inhibition signal, likely by long-
range conformational change through the linker region.
Results
Phosphorylated residue identiﬁcation by mass spectrometry.
To examine the phosphorylation status of human (Hs)MTHFR,
we generated full-length recombinant human MTHFR
(HsMTHFR1–656) by baculovirus expression in Sf9 cells. Mass
spectrometry-based phosphorylation mapping (with 92% cover-
age) identiﬁed 16 separate phosphorylation sites in
HsMTHFR1–656 following puriﬁcation from Sf9 cells (called here
as puriﬁed) (Fig. 2a). All phosphorylation sites were considered to
have partial occupancy, since no residues were phosphorylated in
every tryptic peptide analysed (Supplementary Fig. 1). Of these,
11 phosphorylated amino acids (Ser9, Ser10, Ser18, Ser20, Ser21,
Ser23, Ser25, Ser26, Ser29, Ser30, Thr34) were within the N-
terminal serine-rich region, including the putative phosphoryla-
tion determining residue Thr34 (Fig. 2a). Additionally, we found
phosphorylation of three further amino acids in the catalytic
domain (Tyr90, Thr94, Ser103) and two in the regulatory domain
(Ser394, Thr451). Up to ten phosphorylation sites were identiﬁed
to be occupied simultaneously, whereby treatment with calf
intestine alkaline phosphatase (CIP) resulted in removal of 9
(Fig. 2b) or 10 (Fig. 2c) phosphate groups, as identiﬁed by
Higher animals
(H. sapiens)
Serine-rich
Region Catalytic domain Regulatory domain
Linker
3371 35 48 363 644 656
Lower animals
(C. elegans)
Bacteria
(E. coli, T. thermophilus)
Lower eukaryotes
(S. cerevisiae)
Fig. 1 Schematic representation of MTHFR. Domain organization of MTHFR orthologs across evolution. Numbers given represent approximate amino acid
boundaries in human MTHFR corresponding to NP_005948. In brackets is shown representative species within each category
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denaturing and native mass spectrometry, respectively. To
examine the importance of the N-terminal serine-rich region to
global protein phosphorylation, we produced recombinant
HsMTHFR38–644, which removes the N-terminal 37 amino acids,
including the entire serine-rich region (Fig. 1) as well as the
poorly conserved C-terminal 12 amino acids predicted to be of
high disorder (Supplementary Fig. 2). As puriﬁed
HsMTHFR38–644 was not found to be phosphorylated by phos-
phorylation mapping (Supplementary Fig. 3a), or native mass
spectrometry (Supplementary Fig. 3b), and treatment with CIP
did not alter the protein molecular mass (Fig. 2d). Therefore, the
primary determinant of HsMTHFR phosphorylation resides
within the N-terminus.
Phosphorylation does not alter MTHFR kinetic parameters.
Phosphorylation has been described to alter MTHFR kinetics,
resulting in moderately decreased catalytic activity as measured
by the NADPH-menadione oxidoreductase assay14,16. To inves-
tigate this more thoroughly, we used a very sensitive high-
performance liquid chromatography (HPLC)-based activity assay
which monitors the full enzymatic reaction in the physiological
direction and allows determination of kinetic values18. Overall,
we found similar kinetic values for HsMTHFR1–656 and
HsMTHFR38–644 (Table 1, Supplementary Fig. 4). As described in
Table 1, compared to non-phosphorylated HsMTHFR38–644,
phosphorylated HsMTHFR1–656 had only slightly decreased spe-
ciﬁc activity (34.0 ± 1.3 vs. 30.8 ± 1.5 µmol min−1 mg−1) and kcat
values (51.4 ± 4.2 vs. 40.7 ± 3.2 s−1), suggesting turnover was not
meaningfully reduced. These values are comparable but higher
than previous determinations from recombinant HsMTHFR
(12.4 µmol min−1 mg−1 (ref. 13)) and puriﬁed porcine MTHFR
(19.4 µmol min−1 mg−1 (ref. 19)). Importantly, CIP-treated
HsMTHFR1–656 (dephosphorylated) retained nearly identical
activity values to mock-treated HsMTHFR1–656 (i.e. assay without
addition of CIP; phosphorylated) (Table 1), conﬁrming that
phosphorylation does not decrease enzymatic turnover. Likewise,
Michaelis–Menten constants (KM) for the substrate CH2-THF
(range: 21.3–25.5 µM) and electron donor NADPH (range:
23.5–35.5 µM) were very similar for all four proteins (Table 1),
and comparable to that of MTHFR from human ﬁbroblast lysates
(CH2-THF: 26 µM; NADPH: 30 µM18). Thus, we conclude that
our assay is sensitive and speciﬁc, and that phosphorylation does
not signiﬁcantly alter MTHFR kinetic properties.
Interestingly, we found no increase in the speciﬁc activity of
MTHFR proteins following addition of exogenous FAD to the
assay buffer (Table 1). Since FAD is required as cofactor for the
MTHFR reaction, this suggests the cofactor was already bound to
the as puriﬁed protein, presumably acquired during cellular
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Fig. 2 Phosphorylation status of HsMTHFR1–656 and HsMTHFR38–644. a Phosphorylation mapping of HsMTHFR1–656. The protein sequence is given as amino
acids in single letter code, including the C-terminal His/ﬂag-tag (underlined). Black font represents amino acids identiﬁed by the mass spectrometer
(covered), blue font represents amino acids not identiﬁed (non-covered), red font represents phosphorylated amino acids. Domains are coloured as in
Fig. 1. b Dephosphorylation of HsMTHFR1–656 following treatment with CIP. Treatment time at 37 °C is given. Large number above peaks represents number
of phosphate groups attached. Proteins were analysed by denaturing mass spectrometry. amu, atomic mass units. c Native mass spectrometry analysis of
HsMTHFR1–656 before and after treatment with CIP. Upper panel: as puriﬁed (untreated) protein. Monomer represents protein bound to 1 FAD plus 10
phosphate groups (expected mass: 76831.16 amu); dimer represents protein bound to 2 FADs and 1 SAM plus 20 phosphate groups (expected mass:
154060.74 amu). Lower panel: protein following 180min treatment with CIP. Monomer represents protein bound to 1 FAD (expected mass: 76031.16
amu); dimer represents protein bound to 2 FADs and 1 SAH (expected mass: 152446.74 amu). Expected sizes: protein without ﬁrst methionine, 75245.6
amu; FAD, 785.56 amu; SAM, 398.44 amu; SAH, 384.42 amu, phosphate, 80.00 amu. * indicates a truncated protein representing amino acids 353–663
(expected mass: 36136.6 amu). d HsMTHFR38–644 before and after treatment with CIP. Treatment time at 37 °C is given. Protein was analysed by
denaturing mass spectrometry. e Native mass spectrometry of HsMTHFR1–656 identifying sequential binding of SAM or SAH. Graphs represent areas
zoomed in on dimeric protein. Upper panel: As puriﬁed (untreated) protein. Middle panel: control protein (heated in assay buffer for 180min without CIP).
Bottom panel: treated protein (heated in assay buffer for 180min with CIP). Expected size of protein with 2 FAD bound and 20 phosphates: 153662.3.
Expected size of protein with 2 FAD bound and 0 phosphates: 152062.32. Expected size of SAM: 398.44, SAH: 384.41
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expression. This is consistent with native mass spectrometry,
which identiﬁed monomeric and dimeric forms of as puriﬁed
HsMTHFR1–656 which, in addition to phosphorylation, contained
equivalent units of FAD (Fig. 2c). HsMTHFR38–644 also presented
as monomeric and dimeric forms bound to equivalent units of
FAD (Supplementary Fig. 3b), suggesting phosphorylation has no
effect in this regard. Supplementation with FAD, however, helped
rescue activity when provided either before, or to a lesser extent
following, incubation of these proteins at 46 °C for 5 min
(Table 1). Therefore, this cofactor, which is important for protein
stability, may be lost under heat treatment. In our experiments,
HsMTHFR1–656 was markedly more sensitive to heat inactivation
than HsMTHFR38–644, but this heat sensitivity was not affected by
the phosphorylation state of the protein, and therefore likely
rather reﬂects overall protein stability.
Phosphorylation increases SAM protection and sensitivity. In
addition to phosphorylation and FAD, native mass spectrometry
identiﬁed the dimeric form of as puriﬁed HsMTHFR1–656 to
contain 0, 1 or 2 units of SAM (Fig. 2e). Like FAD, SAM was
likely acquired during cellular expression. However, following
CIP treatment, the SAM bound to MTHFR was found to degrade
to SAH, a chemical transition which did not occur during mock
treatment of the protein (Fig. 2e). Correspondingly, as puriﬁed
dimeric HsMTHFR38–644, which is not phosphorylated, was
found to be bound to 0, 1 or 2 units of SAH, but not SAM
(Supplementary Fig. 3c). Thus, phosphorylated MTHFR appeared
to protect thermally unstable SAM from degradation to SAH,
while the non-phosphorylated protein was unable to perform this
function.
Phosphorylation has been identiﬁed to affect the maximum
degree of inhibition of MTHFR by SAM, whereby phosphorylated
protein was found to be maximally ~80% inhibited, while
phosphatase treated protein was maximally ~60% inhibited14. At
high concentrations of SAM (>200 μM), we were able to inhibit
all recombinant HsMTHFR proteins by over 95%, regardless of
the phosphorylation state (Fig. 3). However, at low SAM
concentrations we found phosphorylated HsMTHFR1–656 to be
more sensitive to SAM inhibition than HsMTHFR38–644 and
dephosphorylated HsMTHFR1–656 (Fig. 3). Further analysis
revealed as puriﬁed and mock-treated HsMTHFR1–656 to have
inhibition constants (Ki) of ~3 µM, while CIP-treated
HsMTHFR1–656 was approximately two-fold less sensitive to
SAM inhibition, and HsMTHFR38–644 seven-fold less sensitive
(Fig. 3, inset; Table 1). Thus, although phosphorylation does not
directly affect MTHFR enzymatic activity, it increases the
protein’s sensitivity to SAM inhibition.
An extensive linker connects and interacts with both domains.
We determined the 2.5 Å resolution structure of HsMTHFR38–644
in complex with FAD and SAH by multiple-wavelength anom-
alous dispersion using the selenomethionine (SeMet) derivatized
protein (Table 2). The identity of both ligands is guided by well-
deﬁned electron density (Supplementary Fig. 5), and in line with
native mass spectrometry analysis for this construct (Supple-
mentary Fig. 3B). The HsMTHFR38–644 protomer folds into two
globular domains (Fig. 4a) to form an overall elongated molecule.
As predicted from bacterial structures, the N-terminal catalytic
domain (aa 40–337) consists of an 8α/8β TIM barrel, adorned
with three extra α-helices (α8, α9 and α11) (Fig. 4a, Supple-
mentary Fig. 6). The C-terminal regulatory domain (aa 363–644)
makes up a novel fold of two ﬁve-stranded β-sheets arranged
side-by-side in the core, ﬂanked by a number of α-helices (Fig. 4a,
Supplementary Fig. 6). The two domains do not contact each
other directly, but instead are connected by an extended linker
region encompassing aa 338–362 (Fig. 4a), with its amino acid
sequence rich in Arg (n= 4), Pro (4), Glu (3) and Leu (3).
Mediated by three β-turns, this linker makes multiple intricate
contacts with both domains, and changes direction twice in tra-
versing between the catalytic and regulatory domains.
The HsMTHFR38–644 structure allows the mapping of the 70
inherited missense mutations known to cause severe MTHFR
Table 1 Kinetic characterization of HsMTHFR
Speciﬁc activity
(µmol min−1 mg−1)
Heat-stable activity (%)a Apparent KM values (µM) Inhibition
(µM)
Protein ØFAD +FAD kcat (s−1) ØFAD Assay+FAD Pre-FAD CH2-THF NADPH NADH SAM Ki (95% CI)
HsMTHFR1–656 30.5 ± 0.9 30.8 ± 1.5 40.7 ± 3.2 33.9 ± 3.1 39.8 ± 1.4 81.0 ± 3.8 22.4 ± 1.3 35.5 ± 2.4 3760 ± 410 2.7 (2.2–3.5)
HsMTHFR38–644 34.8 ± 1.2 34.0 ± 1.3 51.4 ± 4.2 40.7 ± 3.9 83.7 ± 2.8 101.8 ± 3.2 25.5 ± 1.7 23.5 ± 1.7 2160 ± 270 21 (19–23)
HsMTHFR1–656 (mock) 33.6 ± 3.1 32.9 ± 3.7 40.4 ± 4.0 32.6 ± 2.0 40.0 ± 0.8 82.2 ± 2.8 22.5 ± 3.3 30.3 ± 4.0 N.D. 3.8 (3.4–4.3)
HsMTHFR1–656 (CIP) 33.2 ± 1.7 34.4 ± 2.5 39.9 ± 4.2 36.7 ± 1.6 43.2 ± 1.6 81.6 ± 2.7 21.3 ± 1.8 28.7 ± 2.3 N.D. 6.4 (6.1–6.7)
aHeat-stable activity was measured following incubation of the assay mixture for 5 min at 46 °C
ØFAD, FAD was not supplemented; +FAD, FAD was added to the assay buffer after heating; pre-FAD, FAD was added to the protein before heating; N.D., not determined
All values represent the results of at least three separate experiments and are given as ±S.D.
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activity compared to MTHFR incubated without SAM. Inset: Replot of
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log10 to reveal differences between truncated (HsMTHFR38–644) and
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deﬁciency, which lie on 64 different residues of the polypeptide
(Supplementary Fig. 7). Twice as many of the mutation sites are
found in the catalytic domain (n= 38) as the regulatory domain
(20), with the remainder (6) found in the linker region. By
proportion, however, the linker region has a higher density (24%
of the sequence) of mutation sites than the catalytic (11%) and
regulatory (7%) domains. Additionally, a number of sites in the
catalytic and regulatory domains are in direct contact with the
linker region. Further, the most severe mutations, those found
either homozygously or in conjunction with a truncating
mutation to result in enzymatic activity below 1.5% of control
activity in patient ﬁbroblasts20, cluster in the catalytic domain and
the ﬁrst two aa of the linker region, most of which are located
where the linker meets the catalytic domain (Supplementary
Fig. 7). Together, this analysis underscores the importance of the
linker region to proper protein function.
An asymmetric MTHFR dimer with inter-domain ﬂexibility.
The HsMTHFR38–644 structure reveals a homodimer (Fig. 4b),
consistent with native mass spectrometry (Supplementary Fig. 3b)
and previous investigation of mammalian MTHFR by size
exclusion chromatography and scanning transmission electron
microscopy9. It was previously thought that MTHFR homo-
dimerizes in a head-to-tail manner, where the regulatory domain
of one subunit interacts with the catalytic domain of the other
subunit13. Unexpectedly, in our structure dimerization is medi-
ated almost entirely by the regulatory domain (Fig. 4b), although
the ﬁrst ordered residue in chain A (Glu40) is located around 5–6
Å from the regulatory domain of chain B (e.g. Glu553, Arg567).
The N-terminal sequence that is either not present (Ser-rich
phosphorylation region, aa 1–37) or present but disordered (aa
38–39) in the HsMTHFR38–644 structure will likely project
towards the interface of the two regulatory domains (Fig. 4c), and
may contribute further to the dimer contacts.
The essential interfacial residues from the regulatory domain
are contributed predominantly from the two central β-sheets,
including a β-turn (β11–β12), strand β16, and the loop
encompassing Asn386–Asn391 (Supplementary Fig. 8), which
buries in total ~1330 Å2 of accessible surface. Half of the sites of
missense mutations in the regulatory domain causing MTHFR
deﬁciency (n= 10, Supplementary Fig. 7) either participate in, or
are within two residues of, the dimerization site.
Within the homodimer, each of the two catalytic domains is
presented away from the dimeric interface and their active sites
are at opposite ends of the overall shape and face away from each
other (Fig. 4b). In this arrangement, the catalytic domain is not
involved in oligomerization, unlike bacterial and archaeal
MTHFR proteins (Supplementary Fig. 9). This said, the N-
terminus of the HsMTHFR38–644 construct is projecting towards
the dimer interface. A direct consequence of the dimeric
architecture is that the HsMTHFR catalytic domain displays a
large degree of ﬂexibility in relative orientation with the
regulatory domain. In fact, this is reﬂected in our structure
whereby the catalytic domain of one dimer subunit (chain A) is
ordered, while that of the other dimer subunit (chain B) is highly
disordered, to the extent that only main chain atoms of the amino
acid 40–58, 129–134 and 155–342 in chain B could be modelled.
Dynamics of MTHFR observed by solution scattering. Our
HsMTHFR38–644 crystal structure has captured the snapshot of an
asymmetric dimer whereby the two catalytic domains have dif-
ferent orientations with respect to their own regulatory domains
(Supplementary Fig. 10). We applied small-angle X-ray scattering
(SAXS) to understand better the different conformational
Table 2 Data collection and reﬁnement statistics
HsMTHFR38–644 Native ScMET121–301
Native SeMet (MAD)
Data collection
Space group P212121 P212121 P21212
Cell dimensions
a, b, c (Å) 97.3, 127.9, 147.0 97.24, 127.26, 147.29 110.6, 54.5, 61.9
α, β, γ (°) 90.00, 90.00, 90.00 90.00, 90.00, 90.00 90.00, 90.00, 90.00
Peak Inﬂection Remote
Wavelength 0.9281 1.00605 1.00916 0.99835 0.9282
Resolution (Å) 68.53–2.50 (2.64–2.50) 48.62–3.00 (3.11–3.00) 22.75–1.56 (1.60–1.56)
Rsym or Rmerge 8.6 (136.2) 4(57.8) 3.8(58.6) 4.1(60.4) 9.2 (149.8)
I /σI 12.8 (1.2) 18.6(1.2) 18.6(1.2) 18.2(1.1) 14.3 (1.3)
Completeness (%) 100 (100) 100(100) 100(99.9) 100(99.9) 99.5 (99.1)
Redundancy 7.5 (7.0) 2.0(2.0) 2.0(2.0) 2.0(2.0) 8.4 (8.6)
Reﬁnement
Resolution (Å) 96.51–2.50 22.75–1.56
No. of reﬂections (total/unique) 479,094/64,233 448,825/53,602
Rwork/Rfree 21.03/24.75 15.97/19.93
No. of atoms
Protein 8914 2410
Ligand/ion 184 53
Water 72 258
B-factors
Protein 92.29 19.78
Ligand/ion 98.25 23.38
Water 64.09 34.65
R.m.s deviations
Bond lengths (Å) 0.012 0.012
Bond angles (°) 1.296 1.438
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variations assumed by the protein in solution. Superimposition of
the theoretical scattering curve back-calculated from the crystal
structure dimer against experimental data obtained from
HsMTHFR38–644 in solution revealed a poor ﬁt (Chi2 14.8; Fig. 5),
suggesting this is not the predominant conformation in solution.
However, by employing CORAL21 to simulate relaxation of the
relative orientations of the catalytic and regulatory domains (by
allowing ﬂexibility in residues 338–345 of the linker), and thus
also permitting rigid body movement of these subunits in relative
orientation to each other, we obtained a signiﬁcantly improved ﬁt
(Chi2 5.5; Fig. 5). Thus, consistent with our ﬁnding from the
crystal structure, HsMTHFR retains a signiﬁcant degree of intra-
and inter-domain conformational ﬂexibility in solution.
To further investigate the inﬂuence of phosphorylation on
protein conformation, we next collected SAXS data for full-length
HsMTHFR1–656 as puriﬁed (i.e. phosphorylated and bound with
SAM) and treated with CIP (i.e. dephosphorylated and bound
with SAH). The experimental scattering curves for as puriﬁed and
CIP-treated HsMTHFR1–656 gave rise to slightly different proﬁles
and derived parameters (Supplementary Fig. 11, Supplementary
Table 1), although both protein forms are consistent with a
dimeric conﬁguration. These data were further corroborated by
charge radius analysis of native phosphorylated and depho-
sphorylated HsMTHFR1–656 by electrospray ionization mass
spectrometry, showing that the charge-distribution of protein
ions is shifted between the two protein forms. This may indicate a
conformational change equivalent to a 0.5% change in radius
(Supplementary Fig. 12). Together, we interpret these results to
suggest that the phosphorylated SAM-bound form of the protein
may present a different conformation to the dephosphorylated
SAH-bound form, which merits future investigation using
alternative methods.
Subtle features provide for eukaryotic NADPH speciﬁcity. The
MTHFR catalytic domain adopts a TIM-barrel structure evolu-
tionarily conserved across all kingdoms. In addition to
HsMTHFR38–644, we further determined the catalytic domain
structure of the yeast homologue MET12 (ScMET121–301) to 1.56
Å resolution (Table 2). This enables a structural comparison
across mammalian (HsMTHFR), low eukaryotic (ScMET12) and
bacterial (E. coli, H. inﬂuenzae, T. thermophilus) orthologues.
Consistent with their sequence conservation (Supplementary
Fig. 13), the catalytic domains have highly superimposable folds
(main chain RMSD: 1.85 Å), although distinct local differences
are found in low homology loop regions (Fig. 6a, 1–2) and helices
(Fig. 6a, 3–4). Additionally, the ﬁrst helix of the catalytic domain
(α1) is observed in different orientations among these structures
(Supplementary Fig. 14). There is sequence divergence of helix α1
among prokaryotes, lower and higher eukaryotes (Supplementary
Fig. 15). In HsMTHFR (which contains, in its biological sequence
but not present in the crystallized construct, the serine-rich
phosphorylation region N-terminal to the catalytic domain),
ScMET12 and T. thermophilus MTHFR, this helix α1 is projected
towards the interface between catalytic and regulator domains.
In HsMTHFR38–644, clear electron density for FAD was
observed in the TIM barrel of chain A (Supplementary Fig. 5a).
However, there is high disorder in the TIM-barrel of chain B
particularly around the FAD binding site, implying a low ligand
occupancy of the ligand, although native mass spectrometry of
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the crystallized construct indicated two FADs bound per
homodimer (Supplementary Fig. 3b). Analysis of the FAD
binding residues in HsMTHFR chain A (Fig. 6b) reveals perfect
overlap with those predicted from the EcMTHFR structure4.
These include Thr129, Arg157, Ala175 and Ala195 of HsMTHFR,
which were associated with in vitro FAD responsiveness when
mutated in severe MTHFR deﬁciency20,22 (Fig. 6b; Supplemen-
tary Fig. 7).
The bi bi kinetic mechanism of MTHFR necessitates the
electron donor NAD(P)H and substrate CH2-THF to interact in
turn with FAD for transfer of the reducing equivalents, and hence
to share the same binding site. In our structures, the FAD ligand
adopts a conformation poised to expose the si face of the
isoalloxazine ring for the incoming NAPDH and CH2-THF.
However, instead of trapping the electron donor or substrate
(despite multiple attempts at co-crystallization), the binding site
in ScMET121–301 and subunit A of HsMTHFR38–644 is blocked by
a crystal packing interaction from a nearby symmetry mate,
making π–π stacking interactions with the FAD ligand (Supple-
mentary Fig. 16). By contrast, no crystal packing interaction is
found in the chain B binding site of HsMTHFR38–644, explaining
the overall mobility and disorder of its catalytic domain.
Superimposing the HsMTHFR38–644 structure with that of
EcMTHFR bound with NADH (Fig. 6c) and CH3-THF (Fig. 6d)
demonstrates that the human enzyme has largely preserved the
same shared binding site found in prokaryotes, with Gln228,
Gln267, Lys270, Leu271 and Leu323 likely to be important for
interacting with both NAD(P)H and CH3-THF. EcMTHFR
preferentially utilizes NADH23, and its NADH-bound structure
reveals a highly uncommon bent conformation24 for the electron
donor, where the nicotinamide ring stacked over the adenine base
mediates π–π interactions7. Our activity assay of HsMTHFR38–644
and HsMTHFR1–656 clearly demonstrates an ~100-fold preference
for NADPH compared to NADH as an electron donor (Table 1),
in agreement with previous enzyme studies from pig11,25 and
rat11 MTHFRs.
Within the HsMTHFR active site, we did not identify any
obvious differentiating features surrounding the modelled
NADH, which could indicate how the extra 2′-monophosphate
group on the NADPH ribose is accommodated (Supplementary
Fig. 17). It is also unclear if HsMTHFR actually binds NADPH in
a similar manner as NADH for EcMTHFR, considering there is
only one report in the literature documenting a compact stacked
conformation for NADPH26. Modelling an NADPH ligand with
such a stacked conformation onto the HsMTHFR38–644 structure
reveals severe steric clashes with helix α8 (Supplementary Fig. 17),
which creates the ﬂoor of the NAD(P)H binding site (e.g. via
Gln267, Lys270 and Leu271). Helix α8 is poorly aligned with
bacterial and low eukaryotic orthologues in both amino acid
sequence (Supplementary Fig. 13) and structural topology
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(Fig. 6a). The equivalent helix in EcMTHFR harbours the residue
Phe223, which is crucial to NADH binding7 and moves to
accommodate substrate release5. Notably, this residue is not
conserved in HsMTHFR and ScMET12, replaced by Gln267 and
Ala229, respectively. (Supplementary Fig. 13). Therefore, given its
position and mobility, we propose that residue(s) on helix α8 in
HsMTHFR may play a role in the speciﬁcity for NADPH and
likely also substrate binding/release.
A novel fold for the SAM-binding regulatory domain. The
HsMTHFR38–644 structure provides a view of the 3D arrangement
of the regulatory domain unique to eukaryotic MTHFR. The core
of this fold comprises two mixed β-sheets of ﬁve strands each
(β9↑-β17↑-β16↓-β12↑-β11↓ and β10↓-β13↑-β18↓-β14↑-β15↓)
(Supplementary Fig. 6). Strand β10 from one sheet forms a
continuous segment with β11 from the other sheet, and similarly
β12 from one β-sheet continues onto β13 of the other sheet. The
threading of the two central β-sheets are interspersed with three
loop extensions containing different numbers of α-helices (α12–
α15, α16, and α17–α18). To the best of our knowledge, the
MTHFR regulatory domain represents a unique SAM binding
architecture distinct from the 18 known classes of SAM-
dependent methyltransferases and non-methyltransferases27
(Supplementary Fig. 18). Further, a DALI search of this domain28
did not yield any structural homologue, and we found no existing
annotation in PFAM/CATH/SCOP databases and no sequence
for this domain beyond eukaryotic MTHFR homologues.
Therefore, this appears to be a novel fold utilized only by MTHFR
for SAM binding/inhibition.
In our structure, SAH is bound in an extended conformation
within the part of the regulatory domain (Fig. 7a) that faces the
catalytic domain. Indeed, part of the binding site is
constituted by the linker region itself. The ligand is sandwiched
between the loop segment preceding α15 (N456DEPLAAET464)
and the ﬁrst strand β10 (T481INSQ485) of the central
β-sheets, where a number of conserved residues are found.
For example, Thr481 (conserved in 96% of 150 orthologues;
Consurf29) and Ser484 (98%) hydrogen-bond to the SAH
adenine moiety, while Glu463 (99%) and Thr464 (62%) ﬁxate
the ribose hydroxyl groups. The strongest sequence conservation
in the SAH binding site is found around the homocysteine
moiety, including Pro348 (invariant) and Trp349 (99%)
from the linker region, as well as Thr560 and Thr573
(both invariant) at the start and end of the β15-β16 turn.
The SAH homocysteine sulphur atom is loosely contacted by
Glu463 (3.8 Å) and Ala368 (3.7 Å). SAM is expected to
bind to the same site in the regulatory domain, in a similar
extended conﬁguration as SAH and requiring the same
set of binding residues. However, the additional methyl group
in the sulphonium centre of SAM would create a steric
clash to the Ala368 position of the structure (inter-residue
distance ~2.0 Å between heteroatoms, and <1.5 Å between
hydrogen atoms) (Supplementary Fig. 19). Although not
strictly conserved (45% of 150 orthologues), conservation of
Ala368 follows a similar evolutionary pattern as the
MTHFR domain organization (Fig. 1): in higher animals alanine
is invariant; lower animals may accommodate a serine; while
lower eukaryotes often incorporate a bulky residue (e.g. lysine)
(see Supplementary Fig. 15). Therefore, in higher organisms
such as humans, SAM binding likely results in conformational
rearrangement of the loop region containing Ala368 to
accommodate its methyl moiety.
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The linker mediates SAM-dependent conformational change.
Since there is no direct interface between the active site of the
catalytic domain and the regulatory domain (Fig. 4), SAM
binding must elicit enzymatic inhibition via a conformational
change propagated from the regulatory to catalytic domain. The
most likely effector of this conformational change is the extended
linker region (deﬁned as aa 338–362), since it makes multiple
contacts to both the regulatory and catalytic domains (Fig. 4) and
forms part of the SAM/SAH binding site (Fig. 7a). To investigate
the potential of this region to elicit conformational change fol-
lowing SAM binding, we generated recombinant HsMTHFR
proteins consisting of the regulatory domain alone attached to
progressively shorter linker regions, where the N-terminus of
these constructs would become Pro348 (HsMTHFR348–656),
Arg357 (HsMTHFR357–656) and Arg377 (HsMTHFR377–656)
(Fig. 7b; Supplementary Fig. 2). All three constructs are sufﬁcient
to bind SAM and SAH, as demonstrated by dose-dependent
increases in thermostability by differential scanning ﬂuorimetry
when exposed to increasing concentrations of each ligand (Sup-
plementary Fig. 20a). This again reinforces the catalytic and
regulatory domains as separate binding modules for their cognate
ligands (FAD/NADPH/CH3-THF vs SAM/SAH respectively).
We employed analytical size exclusion chromatography (aSEC)
as a means to study solution behaviour of the MTHFR regulatory
domain in response to SAM/SAH binding. Exposure of
MTHFR348–656 to either SAH or SAM resulted in shifts of elution
volume (Ve) compared to as puriﬁed (apo-) protein (Fig. 7b), in
contrast to HsMTHFR1–656 and HsMTHFR38–644, which did not
show changes in Ve despite SAH or SAM binding (Supplementary
Fig. 21). Importantly, for MTHFR348–656, SAM resulted in a
leftward Ve shift (suggestive of a larger hydrodynamic volume)
and SAH a rightward shift (suggestive of a smaller hydrodynamic
volume) (Fig. 7b). By contrast, MTHFR357–656 showed a shift in
Ve only when exposed to SAM, and MTHFR377–656 did not
change when exposed to either ligand (Fig. 7b). A similar pattern
of results were observed when using puriﬁed recombinant mouse
MTHFR of the same protein boundaries (Supplementary Fig. 20a
and b). Therefore, we conclude that residues within 357–377
must contribute to change of protein state upon SAM binding,
which we interpret as a change in conformation.
Next we carried out site-directed mutagenesis to deﬁne residues
involved in SAM binding, and/or SAM-mediated conformational
change as observed in the aSEC experiment. We reasoned that
mutation of Glu463 (which hydrogen-bonds a ribose oxygen) could
lead to loss of SAH/SAM binding, and thus conformational change.
Indeed, conservative mutation of Glu463 to either aspartate (p.
E463D) or glutamine (p.E463Q) on MTHFR348–656 resulted in
protein that could no longer bind SAM (Supplementary Fig. 20c),
nor change conformation in its presence (Fig. 7c). We further
hypothesized that mutation of Ala368 (in close proximity to the
SAM/SAH sulphonium centre) to a smaller residue (glycine: p.
A368G) may not have an effect on binding or conformational
change, while mutation to a larger residue (leucine: p.A368L) might
reduce the ability of the linker region to sense SAM binding.
Correspondingly, p.A368L resulted in protein which retained the
ability to bind SAM, but was less sensitive to change in its presence,
while p.A368G did not change either of these properties. (Fig. 7c,
Supplementary Fig. 20c). These experiments conclusively pinpoint
Glu463 as crucial to SAM binding and Ala368 to SAM sensing,
representing a mechanism that could transmit a ligand-bound
signal from regulatory to catalytic domain of the protein.
Discussion
Catalytic regulation by phosphorylation and SAM binding dis-
tinguishes human MTHFR from its bacterial (which do not have
phosphorylation or SAM binding regions) and lower eukaryotic
(which do not have a phosphorylation region) counterparts. Until
now, the molecular basis of how these two allosteric events
modulate the catalytic machinery was entirely unknown, due to
the absence of a structural context. Now, our structure-guided
study has provided two major discoveries in this area: (1) iden-
tiﬁcation of an extensive linker region that functionally connects
SAM-binding in the regulatory domain with inhibition in the
catalytic domain and (2) demonstration of the concerted effects of
phosphorylation and SAM binding, individually mediated by
regions more than 300 amino acids apart (Supplementary
Fig. 22).
We mapped the entire phosphorylation landscape of
HsMTHFR, revealing phosphorylated Ser/Thr not only at the far
N-terminus (n= 11) as predicted from the sequence but also
within the catalytic (3) and regulatory (2) domains. Many of the
N-terminal phosphorylation sites identiﬁed are consistent with
previous mutation analysis14, including Thr34 (refs. 14–16). The
phosphorylated residues detected in the catalytic and regulatory
domains were not reported before. Interestingly, two phos-
phorylated serines are located within the FAD binding site,
although their physiological signiﬁcance is currently unclear.
Contrary to the recent observation of Li et al.17 we did not
identify phosphorylation of Thr549.
An important ﬁnding with regard to MTHFR phosphorylation
is that it does not directly alter the catalytic parameters of the
enzyme, as determined by a sensitive HPLC-based activity assay.
Perhaps this is not too surprising, since the ﬁrst ordered residue
of the structure, Glu40 (i.e. immediately following the phos-
phorylation region aa 1–37), is far removed from the catalytic site.
Instead, MTHFR phosphorylation exerts a long-range inﬂuence
on the SAM binding status at the regulatory domain some 300
amino acids away, by causing an increased sensitivity of the
enzyme to SAM inhibition, but with no overall changes on total
SAM inhibition. Phosphorylation likely enhances SAM sensitivity
in two interdependent ways. Firstly, it enables protection of
bound SAM from spontaneous degradation to SAH, a phenom-
enon widely observed for SAM-bound enzymes in vitro30 and in
crystallo31, to avoid dis-inhibition by SAH. Secondly, phosphor-
ylation could induce a conformational change to the protein that
primes an inhibition ready state. The SAM Ki differences between
phosphorylated and dephosphorylated protein, while relatively
small (2–3 vs. 6–7 µM), are likely to be physiologically relevant.
Intracellular SAM concentrations are reported to be 1–3 µM in
human cells32,33, and the mTORC1 linked starvation sensor
SAMTOR, which recognizes SAM for nutrient sensing, has a
SAM dissociation constant of 7 µM34.
It is not immediately clear if global phosphorylation or phos-
phorylation of only speciﬁc residues contributed to the results we
found. While 16 phosphorylation sites of HsMTHFR are identi-
ﬁed in this study, intact mass analysis shows that only 9–10
phosphorylations were present at a time, implying a high degree
of heterogeneity. While multiply phosphorylated peptides were
observed, they were not quantiﬁed using our methods. Identiﬁ-
cation of MTHFR proteoforms to assess whether phosphosites
occur in combinations, perhaps using top-down MS35 would be
very interesting, and may constitute the basis of future studies.
Evolutionary conservation of the identiﬁed phosphorylation sites
varies from absolute invariance through to yeast (e.g. Ser394), to
poor conservation even among animals (e.g. Ser9 and Ser10)
(Supplementary Fig. 15). Truncated recombinant
HsMTHFR38–644 was not identiﬁed to be phosphorylated by mass
spectrometry or crystallography, suggesting that phosphorylation
at the far N-terminus primes the other phosphorylation events
within the catalytic and regulatory domains. This is consistent
with previous observations14–16 that removal of Thr34 results in
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non-phosphorylated protein in vitro. It remains to be seen
whether phosphor-Thr34 alone, or other sites at the Ser-rich
region, primes other phosphorylation events in vivo.
We identiﬁed the MTHFR regulatory domain to constitute a
novel SAM binding fold whose appendage to the well-conserved
catalytic TIM-barrel is a relatively recent and contained evolu-
tionary event. A similar phenomenon of domain organization is
found in several eukaryotic enzymes, for example those involved
in amino acid metabolism (e.g. cystathionine β-synthase, CBS36;
phenylalanine hydroxylase, PAH37), whereby the additional
metabolite-binding modules, not found in their bacterial coun-
terparts, serve to ﬁne-tune catalysis in response to the more
intricate higher eukaryotic metabolic and signalling cues. We
propose that MTHFR belongs to this class of allosteric enzymes
that share a common mechanism—to regulate catalysis through
steric sequestration of the catalytic site, in a ligand-dependent
manner (SAM for MTHFR and CBS; phenylalanine for PAH).
Although our crystal structure represents a static snapshot of
the enzyme state (likely a dis-inhibited state due to SAH binding),
the potential for inter-domain conformational changes is sug-
gested by the following data. Firstly, the two chains in the crystal
asymmetric unit show varying intrinsic order of the catalytic
domain with respect to the regulatory domain. Secondly, SAXS
and native mass spectrometry analysis between SAM-bound
phosphorylated protein and SAH-bound dephosphorylated pro-
tein hint at subtle, but distinguishable changes to the protein
dimensions. It remains to be determined from future studies
whether MTHFR undergoes ligand-dependent conformational
changes to rearrange domain orientation for catalysis, like PAH
and CBS. If this should be the case, the MTHFR linker region will
likely contribute to this role, as it makes extensive contacts with
both the regulatory domain (e.g. SAM binding site) and catalytic
domain (e.g. helices α3 and α4). This is also consistent with the
concentration of deleterious disease mutations found in this
region. Additional genetic data from our lab are in accord20, as
patient ﬁbroblasts homozygous for p.His354Tyr, a linker residue
which contacts helix α3 in catalytic domain, exhibited a ﬁve-fold
decrease in Ki for SAM.
So in what aspects could the SAM-bound signal inﬂuence the
catalytic domain, seeing that its kinetic parameters remain largely
unaltered? One possibility is an effect on the stability or integrity
of FAD, the essential cofactor. We observed that supplementation
with FAD enabled rescue of activity to our recombinant MTHFR.
This is indicative of cofactor loss, in agreement with previous
ﬁndings13, and suggestive of FAD being only loosely bound, as
exempliﬁed in chain B of our structure. Furthermore, a number of
MTHFR mutations20,22 and polymorphisms13 are shown to affect
FAD responsiveness. It is therefore possible that the inter-domain
ﬂexibility we observed, communicated by the SAM-bound signal,
would alter the orientation of catalytic domains with respect to
the rest of the protein, in a similar manner as the multi-domain
enzymes CBS and PAH38. Such structural conformations are
supported by overlays between chains A and B in our structure,
and between apo- and holo-subunits in TtMTHFR8. In the case of
MTHFR, the active site could be more sequestered (leading to
FAD bound) or more exposed and mobile (leading to FAD loss)
as a consequence.
The SAM/SAH ratio is regarded as an indicator of a cell’s
methylation potential and is a crucial indicator of the cells’
capacity to perform DNA methylation or create compounds
which require methyl groups for assimilation. In the face of a low
SAM/SAH ratio, meaning methyl donor deﬁciency, MTHFR is
dis-inhibited, increasing the production of CH3-THF to improve
throughput of the methionine cycle and replenish SAM levels.
Conversely, a high SAM/SAH ratio means abundant methylation
capacity, in which case SAM-mediated allosteric inhibition of
MTHFR turns off CH3-THF production, thereby lowering
methionine cycle activity and concomitantly generation of SAM.
This on/off switch is especially powerful at high SAM levels, as
illustrated by almost complete inhibition of recombinant
HsMTHFR at >200 µM SAM. Although these types of con-
centrations are unlikely to be seen inside the cell, HsMTHFR has
been further outﬁtted with a dimmer switch, whereby protein
phosphorylation increases sensitivity to SAM-mediated inhibition
at normal (1–10 µM) cellular SAM levels. In this regard, phos-
phorylation allows linkage of the methionine cycle to other cel-
lular pathways (e.g. cell cycle) through speciﬁc kinase activities (as
suggested by Zhu et al.16 and Li et al.17).
The clear correlation we observed between phosphorylated
MTHFR with SAM binding in solution (vs dephosphorylated
MTHFR and SAH binding) leads us to interpret that the two
regulatory properties act in concert. In fact, the architecture of the
HsMTHFR homodimer is smartly tailor-made to facilitate this
correlation. (1) The dimeric interface is entirely constituted by the
regulatory domain to form a scaffold, while leaving each SAM
binding site on a different face for its sensing and signal trans-
mission functions. (2) The lack of contacts between inter-
monomeric catalytic domains allows for the intrinsic intra-
monomeric mobility with respect to the regulatory domains for
signal propagation. (3) Importantly, this dimeric conﬁguration
brings the N- and C-termini of the polypeptide in proximity,
projecting the phosphorylation region close to the regulatory
domain dimer interface.
In summary, we provide a structural view of a eukaryotic
MTHFR, pointing to the linker region playing a direct role in
allosteric inhibition following SAM binding, and phosphorylation
as a means to modulate SAM inhibition sensitivity. Modulating
such ﬁnite control towards the level of a key metabolite may be of
pharmacological interest, including in cancer metabolism39,40.
Our work here constitutes a strong starting point for future, more
precise investigation by structural, biochemical and cellular stu-
dies, for example towards: identiﬁcation of the kinase(s)
responsible for MTHFR phosphorylation in vivo; combining
different structural methods to delineate conformational changes
of the entire protein, and revealing the molecular basis of its
speciﬁcity over NADPH.
Methods
Recombinant production of MTHFR. Numbering of the nucleotide changes fol-
lows the nomenclature of NM_005957.4, which places the A of the ATG initiation
codon as the +1 nucleotide. The protein is numbered according to NP_005948.3.
For E. coli (BL21(DE3)R3) expression, DNA fragments encoding human MTHFR
(IMAGE: 6374885), mouse MTHFR (IMAGE: 6834886) and yeast MET12 (clone:
ScCD00096551 from Harvard Medical School) harbouring different N- and C-
terminal boundaries were ampliﬁed and subcloned in pNIC28-Bsa4 vector
(accession number: EF198106) in-frame with a tobacco etch virus protease clea-
vable N-terminal His6-tag. For baculovirus expression, DNA fragments encoding
human MTHFR (IMAGE: 6374885) harbouring different N- and C-terminal
boundaries were cloned into the pFB-CT10HF-LIC vector (Addgene plasmid:
39191) in-frame with a tobacco etch virus protease cleavable C-terminal ﬂag/His10-
tag. Site-directed mutations were constructed using the QuikChange mutagenesis
kit (Stratagene) and conﬁrmed by sequencing. All primers are available upon
request. Proteins expressed in E. coli were puriﬁed by afﬁnity (Ni-Sepharose; GE
Healthcare) and size exclusion (Superdex 200; GE Healthcare) chromatography.
Proteins expressed in insect cells in Sf9 media (ThermoFisher) were puriﬁed by
afﬁnity (Ni-NTA, Qiagen) and size exclusion (Superdex 200) chromatography,
followed by cleavage of the C-terminal tag by His-tagged tobacco etch virus pro-
tease (1:20 mass ratio) overnight at 4 °C and re-passaged over Ni-NTA resin.
Selenomethionine (SeMet)-derivatized proteins were expressed using Seleno-
Methionine Medium Complete (Molecular Dimensions) and puriﬁed as above.
Crystallization and structure determination. Puriﬁed native ScMET121–302 as
well as SeMet-derivatized and native HsMTHFR38–644 were concentrated to 15–20
mgmL−1, and crystals were grown by sitting drop vapour diffusion at 20 °C. The
mother liquor conditions are summarized in Table 2. Crystals were cryo-protected
in mother liquor containing ethylene glycol (25% v/v) and ﬂash-cooled in liquid
nitrogen. X-ray diffraction data were collected at the Diamond Light Source and
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processed using XIA2 (ref. 41). The HsMTHFR38–644 structure was solved by
selenium multi-wavelength anomalous diffraction phasing using autoSHARP42,
and subjected to automated building with BUCCANEER43. The SeMet model was
used to solve the native structure of HsMTHFR38–644 by molecular replacement
using PHASER44. This structure was reﬁned using PHENIX45, followed by manual
rebuilding in COOT46. Phases for ScMET121–302 were calculated by molecular
replacement using 3APY as model. Atomic coordinates and structure factors for
both ScMET121–302 (accession code: 6FNU) and HsMTHFR38–644 (accession code:
6CFX) have been deposited in the Protein Data Bank. Data collection and
reﬁnement statistics are summarized in Table 2. The ﬁnal models of
HsMTHFR38–644 and ScMET121–302 contain respectively 95.6% and 98.6% in the
favoured region, 4.3% and 1.1% in the allowed region, and 0.17% and 0.36% in the
outlier region of the Ramachandran plot.
MTHFR assay. All enzymatic assays, including SAM inhibition and thermolability,
were performed using the physiological forward assay described by Suormala et al.18
with modiﬁcations as described by Rummel et al.47 and Burda et al.20,22. Only
minor adaptations were made for use with pure protein, including reducing the
assay time to 7min and the addition of bovine serum albumin (BSA) to keep
puriﬁed proteins stable. Prior to assay, puriﬁed proteins were diluted from 15–20 to
1mgmL−1 in 10mM HEPES-buffer pH 7.4, 5% glycerol and 500mM NaCl fol-
lowed by successive dilutions of 1:100 and 1:32 in 10mM potassium phosphate, pH
6.6 plus 5 mgmL−1 BSA, to a ﬁnal MTHFR concentration of 312.5 ng mL−1.
Speciﬁc activity was measured in 50mM potassium phosphate buffer, pH 6.6, under
saturating substrate concentrations (75 µM methyleneTHF, Eprova AG; 200 µM
NADPH; Sigma-Aldrich) with and without the addition of FAD (75 µM; Sigma-
Aldrich). The KM for NAPDH was determined by varying its concentration between
10 and 250 µM in the presence of 75 µM CH2-THF. The KM for CH2-THF was
determined by varying its concentration between 2.5 and 100 µM in the presence of
75 µM NAPDH. All KM values were derived using a non-linear ﬁt of
Michaelis–Menten kinetics by GraphPad Prism (v6.07). For SAM inhibition, pur-
iﬁed SAM48 was used. The Ki was estimated following a plot of log(inhibitor) vs.
response and a four parameter curve ﬁt as performed by GraphPad Prism (v6.07).
In-solution analysis. Analytical gel ﬁltration was performed on a Superdex 200
HiLoad 10/30 column (GE Healthcare) pre-equilibrated with 10 mM HEPES pH
7.5, 150 mM NaCl and 5% glycerol in the presence or absence of 250 µM SAH or
SAM (both Sigma-Aldrich). The column was calibrated using carbonic anhydrase
(29 kDa), BSA (66 kDa), alcohol dehydrogenase (150 kDa) and apoferritin (443
kDa) as protein standards. Differential scanning ﬂuorimetry was used to assay
shifts in melting temperature caused by ligand binding in a 96-well PCR plate using
an LC480 light cyler (Roche). Each well (20 µL) consisted of protein (0.1 mgmL−1),
SYPRO-Orange (Invitrogen) diluted 1000× and buffer (10 mM HEPES pH 7.5, 500
mM NaCl) in the presence of 0–250 µM SAM or SAH. Fluorescent intensities were
measured from 20 to 78 °C with a ramp rate of 1 °C min−1. The temperature shifts,
ΔTmobs, were calculated using a Boltzmann sigmoidal ﬁt49, and half-maximal
effective ligand concentrations, AC50, for each ligand was ﬁt to a one-site total
binding model, both using GraphPad Prism (v6.07).
Small-angle X-ray scattering. SAXS experiments for the HsMTHFR38–644 and
HsMTHFR1–656 (phosphorylated and dephosphorylated) were performed at 0.99 Å
wavelength Diamond Light Source at beamline B21 coupled to the Shodex KW403-4F
size exclusion column (Harwell, UK) and equipped with Pilatus 2M two-dimensional
detector at 4.014m distance from the sample, 0.005 < q < 0.4 Å−1 (q= 4π sin θ λ−1, 2θ
is the scattering angle). The samples (20mgmL−1) were in a buffer containing 20mM
Hepes-NaOH pH 7.5, 0.5mM TCEP, 150mM NaCl, 2% glycerol and 1% sucrose.
SAXS measurements were performed at 20 °C, using an exposure time of 3 s frame−1.
To perform dephosphorylation, as puriﬁed (phosphorylated) HsMTHFR1–656 was
added with 10mM Mg-acetate in the above buffer and incubated with 100U calf
alkaline phosphatase at 37 °C for 2 h. SAXS data were processed and analysed using
the ATSAS program package21 and Scatter (http://www.bioisis.net/scatter). The radius
of gyration Rg and forward scattering I(0) were calculated by Guinier approximation.
The maximum particle dimension Dmax and P(r) function were evaluated using the
programme GNOM50. To demonstrate the absence of concentration-dependent
aggregation and interparticle interference in the both SAXS experiments, we inspected
Rg over the elution peaks and performed our analysis only on a selection of frames in
which Rg was most stable. Overall, such stability of Rg over the range of con-
centrations observed in the SEC elution indicates that there were no concentration-
dependent effects or interparticle interference. Ten runs of CORAL rigid body
modelling were performed by deﬁning residues 338–345 as a ﬂexible linker and
allowing the catalytic subunits to move while keeping the regulatory subunits ﬁxed.
Denaturing intact mass analysis. Reversed-phase chromatography was per-
formed in-line prior to mass spectrometry using an Agilent 1290 uHPLC system.
Concentrated protein samples were diluted to 0.02 mgmL−1 in 0.1% formic acid
and 50 µL was injected on to a 2.1 mm × 12.5 mm Agilent Zorbax 5um 300SB-C3
guard column housed in a column oven set at 40 °C. The solvent system used
consisted of 0.1% formic acid in LC-MS grade water (solvent A) and 0.1% formic
acid in LC-MS grade methanol (solvent B). Chromatography was performed as
follows: initial conditions were 90% A and 10% B and a ﬂow rate of 1.0 mLmin−1.
A linear gradient from 10% B to 80% B was applied over 35 s. Elution then
proceeded isocratically at 95% B for 40 s followed by equilibration at initial con-
ditions for a further 15 s. Protein intact mass was determined using a 6530 QTOF
mass spectrometer (Agilent). The instrument was conﬁgured with the standard ESI
source and operated in positive ion mode. The ion source was operated with the
capillary voltage at 4000 V, nebulizer pressure at 60 psig, drying gas at 350 °C and
drying gas ﬂow rate at 12 L min−1. The instrument ion optic voltages were as
follows: fragmentor 250 V, skimmer 60 V and octopole RF 250 V.
Native mass spectrometry. Mass spectrometry of MTHFR under native condi-
tions was performed on the same MS instrument, and is described in detail else-
where51. Brieﬂy, 50 µg of protein was desalted and exchanged into 50 mM
ammonium acetate pH 6.5 using three rounds of size exclusion spin column
puriﬁcation ("Micro BioSpin 6", Biorad) following the manufacturer’s instructions.
Approximately 50 µL was infused directly into the mass spectrometer via syringe
pump at a rate of 6 µL min−1. The instrument was ﬁtted with a standard source
using a nebulizer pressure of 17 psi, drying gas ﬂow rate 5 L min−1 and drying gas
temperature 325 °C. The instrument was operated in positive ion, 1 GHz detector
mode with fragmentor voltage 430 V, nebulizer pressure set to 17 psi, and collision
gas pressure and energy at 0. Spectra were deconvoluted using the MaxEnt func-
tionality within the Masshunter software package (Agilent) and multimeric states
were determined manually using a charge table. The radius for native protein
charge states was determined using the calculation z= R1.5 or R= z × 101/1.5 where
z is the charge state and R is the radius in Ångstroms if the protein is assumed to be
a sphere52. To allow comparison between spectra, ion intensities were normalized
by dividing each value by the largest in that spectrum. Normalized ion intensity
was plotted against charge radius for each ion.
Phosphorylation mapping. Between 20 and 100 µg MTHFR was reduced in 100
µL of 100 mM ammonium bicarbonate buffer, pH 7.5 by addition of 1 µL of 1M
DTT and incubation at 56 °C for 40 min. Alkylation was performed by addition of
4 µL of saturated iodoacetamide solution and incubated at room temperature in the
dark for 20 min. Endoprotease digestion was performed using either trypsin, Smart
Digest trypsin (Thermo) or pepsin. Trypsin in 100 mM ammonium bicarbonate
buffer, pH 7.5 was added in the ratio 20:1 w/w and incubated at 37 °C overnight.
Smart Digest trypsin was incubated at 70 °C for 1 h following the manufacturer’s
instructions. Pepsin digestion was performed in 0.1 M HCl in the ratio 20:1 w/w
and incubated at 37 °C overnight. LC-MSMS analyses were performed using both
whole endoprotease digests and metal oxide-afﬁnity enriched samples. Metal
oxide-afﬁnity enrichment for phosphopeptides was performed using home made
spin columns containing a mixed bed of 2.5 mg Titansphere TiO2 chromatography
matrix (GL Sciences) and 2.5 mg ZrO2 powder. Non-phospopeptides were eluted
using 80% ACN, 300 mgmL−1 DHB, 0.1% TFA. Phosphopeptides were eluted in
25% ammonium hydroxide, 40% ACN. Samples were dried-down by rotary eva-
poration and re-suspended in 5 µL of 2% ACN, 0.1% FA prior to LC-MSMS.
Analysis was performed using a Dionex U3000 nanoHPLC coupled to a Bruker
Esquire HCT ion trap mass spectrometer. Peptides were separated using a 200
µm × 5 cm Pepswift PS-DVB monolithic column (Thermo, USA). A gradient was
developed from 2 to 17% B over 4 min, then 17–42% B over 2 min. The column
was washed at 92% B for 1 min and ﬁnally equilibrated at 2% B for 6 min at a ﬂow
rate of 2.5 µL min−1. Buffer A was 0.1% formic acid in LC-MS grade water: Buffer
B was 0.1% formic acid, 80% LC-MS grade ACN. MSMS was performed in data-
dependent mode with a scan rate of 26,000 m z−1 s−1 with three precursors per
MS1 scan and active exclusion for 20 s. Charge state selection was +1, +2 and +3.
Automated data analysis was performed using Data Analysis v 4.0 (Bruker).
Database searching was performed using an in-house Mascot server, in which the
MTHFR database was searched for variable modiﬁcations including oxidation (M)
and phosphorylation (ST or Y) with an MS tolerance of 1.4 Da, MSMS tolerance of
0.5 Da, partials at 4, C13 at 1 and charge states of +1, +2, +3. All putative
phosphopeptide assignments were evaluated manually with an assumed false
discovery rate of zero. Composite MSMS for MTHFR coverage was 92%.
Data availability. The crystal structures of HsMTHFR and ScMET12 have been
deposited in the protein data bank (PDB) with the identiﬁers 6CFX and 6FNU,
respectively. The full mass spectrometry phosphorylation dataset has been submitted
to MassIVE with the accession number MSV000082179. All other data are available
from the corresponding authors upon reasonable request.
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